TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention
3000 patients around the world
Available in Brazil, Mexico, United States, Uruguay
In BRCA1/2 gene mutation carriers, a risk-reducing salpingo-oophorectomy (RRSO) is
recommended around the age of 40. This recommendation is based on a 10-40% life-time risk of
ovarian cancer in this population and disappointing results of ovarian cancer surveillance
for early detection. Moreover, the mortality rate of ovarian cancer is high. Effects of RRSO
are a decrease in ovarian cancer risk (80-96%) on one hand and immediate onset of menopause
and non-cancer related morbidity on the other hand. The fifty percent breast cancer risk
reduction after RRSO has become disputable in the last years. Based on multiple studies
showing that most high-grade serous ovarian cancers develop at the distal end of the
Fallopian tube, an innovative strategy for RRSO has been developed for this study proposal:
risk-reducing salpingectomy (RRS) with delayed risk-reducing oophorectomy (RRO). However, the
safety of this strategy has not been proven yet. Before implementing this innovative strategy
as standard care we need to investigate the long term effects on ovarian cancer incidence.